BridgeBio Pharma (BBIO)

(10% Negative) BridgeBio Pharma, Inc. (BBIO) Announces Delay in million Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations

AVROBIO Inc (AVRO)

(10% Negative) AVROBIO, INC. (AVRO) Announces Delay in trial Trials for Pompe disease Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment